HK1161988A1 - 包含 -氧代- -吡咯烷衍生物的藥物組合物 - Google Patents

包含 -氧代- -吡咯烷衍生物的藥物組合物

Info

Publication number
HK1161988A1
HK1161988A1 HK12102566.6A HK12102566A HK1161988A1 HK 1161988 A1 HK1161988 A1 HK 1161988A1 HK 12102566 A HK12102566 A HK 12102566A HK 1161988 A1 HK1161988 A1 HK 1161988A1
Authority
HK
Hong Kong
Prior art keywords
oxo
pharmaceutical compositions
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
HK12102566.6A
Other languages
English (en)
Inventor
．卡普爾斯
．貝爾韋爾
．法納拉
．巴瑞拉羅
Original Assignee
生物製藥私人有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生物製藥私人有限公司 filed Critical 生物製藥私人有限公司
Publication of HK1161988A1 publication Critical patent/HK1161988A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12102566.6A 2009-01-29 2012-03-14 包含 -氧代- -吡咯烷衍生物的藥物組合物 HK1161988A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09100083 2009-01-29
PCT/EP2010/050892 WO2010094535A1 (en) 2009-01-29 2010-01-27 Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
HK1161988A1 true HK1161988A1 (zh) 2012-08-17

Family

ID=40622206

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12102566.6A HK1161988A1 (zh) 2009-01-29 2012-03-14 包含 -氧代- -吡咯烷衍生物的藥物組合物
HK14111804.7A HK1198287A1 (zh) 2009-01-29 2014-11-21 包含 -氧代- -吡咯烷衍生物的藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14111804.7A HK1198287A1 (zh) 2009-01-29 2014-11-21 包含 -氧代- -吡咯烷衍生物的藥物組合物

Country Status (23)

Country Link
US (2) US20120108464A1 (zh)
EP (1) EP2391349B1 (zh)
JP (1) JP5576401B2 (zh)
KR (1) KR101640164B1 (zh)
CN (2) CN104083328B (zh)
AU (1) AU2010215646B2 (zh)
BR (1) BRPI1007161B1 (zh)
CA (1) CA2747395C (zh)
CY (1) CY1115673T1 (zh)
DK (1) DK2391349T3 (zh)
EA (1) EA022057B1 (zh)
ES (1) ES2511047T3 (zh)
HK (2) HK1161988A1 (zh)
HR (1) HRP20141006T1 (zh)
IL (1) IL213545A (zh)
ME (1) ME01927B (zh)
MX (1) MX2011007267A (zh)
PL (1) PL2391349T3 (zh)
PT (1) PT2391349E (zh)
RS (1) RS53554B1 (zh)
SI (1) SI2391349T1 (zh)
SM (1) SMT201400155B (zh)
WO (1) WO2010094535A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300562A (zh) * 2009-01-29 2011-12-28 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的药物组合物
CN104800176A (zh) * 2015-04-23 2015-07-29 广东赛烽医药科技有限公司 一种布瓦西坦口崩片及其制备方法
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
WO2019036713A1 (en) * 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
CN109833300A (zh) * 2017-11-28 2019-06-04 浙江京新药业股份有限公司 一种抗癫痫药物口服组合物及其制备方法
CA3097340A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
CN113288872A (zh) * 2020-02-21 2021-08-24 广东东阳光药业有限公司 一种2-吡咯烷酮衍生物的组合物及其制备方法
CN112933059A (zh) * 2021-03-25 2021-06-11 浙江昂利康制药股份有限公司 一种布立西坦片剂的干法制粒工艺
CN115192572B (zh) * 2021-04-08 2023-09-19 成都同道慧宜生物医药科技有限公司 布立西坦药剂、其制备方法和应用
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
JP2005298338A (ja) 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
CN1186094C (zh) * 2002-07-01 2005-01-26 蔡海德 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法
WO2006099005A1 (en) * 2005-03-09 2006-09-21 Trustees Of Dartmouth College Method for identifying agents which modulate gtpase activity involved in insulin-stimulated glut4 translocation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
MX2007004294A (es) * 2005-07-26 2008-03-11 Ucb Pharma Sa Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
ES2444009T3 (es) 2006-06-08 2014-02-21 Ucb Pharma, S.A. Co-cristales de pirrolidinonas
US20080069878A1 (en) * 2006-08-31 2008-03-20 Gopi Venkatesh Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
US20080280862A1 (en) * 2007-01-05 2008-11-13 Cermak Jennifer M Methods, compositions, and kits for the treatment of pain
CN102300562A (zh) * 2009-01-29 2011-12-28 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的药物组合物

Also Published As

Publication number Publication date
IL213545A0 (en) 2011-07-31
WO2010094535A1 (en) 2010-08-26
HRP20141006T1 (hr) 2014-12-19
IL213545A (en) 2016-05-31
HK1198287A1 (zh) 2015-03-27
EP2391349B1 (en) 2014-07-23
ES2511047T3 (es) 2014-10-22
BRPI1007161A2 (pt) 2016-02-23
BRPI1007161B1 (pt) 2022-03-22
EA022057B1 (ru) 2015-10-30
CA2747395A1 (en) 2010-08-26
RS53554B1 (en) 2015-02-27
CN102292071A (zh) 2011-12-21
CN102292071B (zh) 2016-08-24
PL2391349T3 (pl) 2014-12-31
KR20120008022A (ko) 2012-01-25
AU2010215646B2 (en) 2014-03-27
KR101640164B1 (ko) 2016-07-15
JP2012516302A (ja) 2012-07-19
CY1115673T1 (el) 2017-01-25
EA201101116A1 (ru) 2012-03-30
DK2391349T3 (da) 2014-11-03
ME01927B (me) 2015-05-20
SMT201400155B (it) 2015-01-15
US20120108464A1 (en) 2012-05-03
US10729653B2 (en) 2020-08-04
AU2010215646A1 (en) 2011-08-04
MX2011007267A (es) 2011-08-15
EP2391349A1 (en) 2011-12-07
PT2391349E (pt) 2014-10-27
US20110281929A1 (en) 2011-11-17
CN104083328A (zh) 2014-10-08
SI2391349T1 (sl) 2014-12-31
JP5576401B2 (ja) 2014-08-20
CN104083328B (zh) 2017-04-12
CA2747395C (en) 2015-01-13

Similar Documents

Publication Publication Date Title
HK1218881A1 (zh) 藥物組合物
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
HK1198287A1 (zh) 包含 -氧代- -吡咯烷衍生物的藥物組合物
EP2451274A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
HK1209649A1 (zh) 含有 -氧代- -吡咯烷衍生物的藥物組合物
PL2323623T3 (pl) Kompozycje farmaceutyczne
IL215497A0 (en) Oxadiazile derivatives and pharmaceutical compositions containing them
GB0902648D0 (en) Pharmaceutical compounds and compositions
IL219018A0 (en) Pharmaceutical compositions
IL206487A0 (en) Pharmaceutical compositions
EP2473168A4 (en) PHARMACEUTICAL FORMULATIONS FOR INDIBULIN
GB0800659D0 (en) Pharmaceutical Compositions
GB0910225D0 (en) Pharmaceutical compositions
GB0806283D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0908069D0 (en) Pharmaceutical compounds and compositions
GB0902651D0 (en) Pharmaceutical compounds and compositions
GB0903945D0 (en) Pharmaceutical compounds and compositions